{"id":63123,"date":"2026-05-22T13:24:50","date_gmt":"2026-05-22T12:24:50","guid":{"rendered":"https:\/\/www.promedical.co.uk\/?p=63123"},"modified":"2026-05-22T13:24:50","modified_gmt":"2026-05-22T12:24:50","slug":"elective-recovery-is-improving-but-not-yet-secure","status":"publish","type":"post","link":"https:\/\/www.promedical.co.uk\/healthcare-leadership\/elective-recovery-is-improving-but-not-yet-secure\/","title":{"rendered":"Elective Recovery Is Improving, But Not Yet Secure"},"content":{"rendered":"

The March 2026 NHS England Board papers show that elective recovery is moving in the right direction, but not yet on secure footing.<\/span>\u00a0<\/span><\/p>\n

The total elective waiting list has reduced. Long waits are falling. The under-18 waiting list is lower than a year earlier. Referral to Treatment performance has improved compared with January 2025. These are important signs of recovery, and they should not be understated.\u00a0<\/span>\u00a0<\/span><\/p>\n

But the same Board pack shows why the system cannot yet treat elective recovery as structurally stable. The waiting list\u00a0remains\u00a0very large, 18-week performance is still below the 2025\/26 requirement, provider-level variation\u00a0remains\u00a0significant, diagnostics are not keeping pace with demand, and the wider operating environment is financially constrained.\u00a0<\/span>\u00a0<\/span><\/p>\n

The core signal is therefore not \u201celective recovery has been solved\u201d.\u00a0It is more precise:\u00a0<\/span>elective recovery is improving, but the next phase will depend on whether systems can convert short-term activity gains into sustained pathway improvement.<\/span><\/b><\/p>\n

The headline waiting list is moving in the right direction<\/h3>\n

The most visible positive signal is the reduction in the total elective waiting list.<\/span>\u00a0<\/span><\/p>\n

NHS England\u2019s Integrated Performance Report shows that the total waiting list stood at\u00a0<\/span>7,247,214<\/span><\/b>\u00a0in January 2026. This was down from\u00a0<\/span>7,290,880<\/span><\/b>\u00a0in December 2025, a reduction of\u00a0<\/span>43,666 patients<\/span><\/b>, and down from\u00a0<\/span>7,427,669<\/span><\/b>\u00a0in January 2025, a year-on-year reduction of\u00a0<\/span>180,455 patients<\/span><\/b>.\u00a0<\/span>\u00a0<\/span><\/p>\n

That movement matters because it shows that national and regional recovery actions are producing measurable improvement. NHS England\u00a0identifies\u00a0validation incentivisation, enhanced national and regional oversight through tiering, a Q4 performance sprint on\u00a0additional\u00a0elective activity, and Getting It Right\u00a0First Time\u00a0support as part of the current recovery approach.\u00a0<\/span>\u00a0<\/span><\/p>\n

There\u00a0is\u00a0also a positive children and young people signal. The under-18 elective waiting list stood at\u00a0<\/span>740,420<\/span><\/b>\u00a0for the week ending 22 February 2026, down from\u00a0<\/span>771,515<\/span><\/b>\u00a0for the equivalent week in February 2025. This\u00a0represents\u00a0a year-on-year reduction of\u00a0<\/span>31,095\u00a0patients<\/span><\/b>. NHS England states that it continues to\u00a0monitor\u00a0the children and young people elective waiting list across a range of metrics to ensure improvement activity is\u00a0equitable.\u00a0<\/span>\u00a0<\/span><\/p>\n

For patients and families, these reductions are meaningful. Fewer people waiting, and fewer children waiting, means less exposure to delay,\u00a0uncertainty\u00a0and deterioration. But the scale of the remaining list means the system is still managing\u00a0a very large\u00a0access challenge.<\/span><\/p>\n

RTT improvementremainsbelow the required trajectory<\/h3>\n

The second signal is more cautious. Referral to Treatment performance is improving, but not yet enough.<\/span>\u00a0<\/span><\/p>\n

In January 2026,\u00a0<\/span>61.5%<\/span><\/b>\u00a0of elective patients were waiting less than 18 weeks for treatment. That was unchanged from December 2025 and up from\u00a0<\/span>58.9%<\/span><\/b>\u00a0in January 2025. The improvement is real, but NHS England\u2019s own report states that RTT is the main elective performance priority for 2025\/26 and 2026\/27, and that the 2025\/26 requirement is\u00a0<\/span>65%<\/span><\/b>.\u00a0<\/span>\u00a0<\/span><\/p>\n

This creates a clear delivery gap. The system is improving year on year, but January 2026 performance remained below the current requirement. That matters because elective recovery cannot be judged only by the size of the waiting list. It must also be judged by how quickly patients are moving through pathways.<\/span>\u00a0<\/span><\/p>\n

Long waits show a stronger improvement trend. The proportion of elective patients waiting over 52 weeks was\u00a0<\/span>1.87%<\/span><\/b>\u00a0in January 2026, equivalent to\u00a0<\/span>135,657 patients<\/span><\/b>. This was down from\u00a0<\/span>2.68%<\/span><\/b>\u00a0in January 2025. NHS England\u00a0identifies\u00a0reduction of the longest waits as a continuing priority and a focus of performance oversight with regions and providers in elective tiering.\u00a0<\/span>\u00a0<\/span><\/p>\n

The strategic implication is that recovery is uneven across different access measures. The system is reducing the longest waits, but 18-week performance still requires further acceleration. For provider leaders, that means the next phase is not only about doing more activity. It is about improving throughput, clinical prioritisation, pathway\u00a0discipline\u00a0and the reliability of conversion from referral to treatment.<\/span><\/p>\n

Variation is now one of the central risks<\/h3>\n

The March Board pack shows significant variation across both integrated care boards and acute providers.<\/span>\u00a0<\/span><\/p>\n

At ICB level, the number of patients on the elective waiting list in January 2026 ranged from\u00a0<\/span>51,772<\/span><\/b>\u00a0at the lowest end to\u00a0<\/span>413,539<\/span><\/b>\u00a0at the highest end. These figures should not be read as a simple performance league table, because population size, referral patterns, provider\u00a0configuration\u00a0and local demand all differ. But the range still shows that elective pressure is not distributed evenly across the NHS.\u00a0<\/span>\u00a0<\/span><\/p>\n

Provider-level RTT variation is also material. In January 2026, 18-week RTT performance across acute providers ranged from\u00a0<\/span>97.5%<\/span><\/b>\u00a0at the highest end to\u00a0<\/span>48.9%<\/span><\/b>\u00a0at the lowest end. The\u00a0proportion of patients waiting over 52 weeks also varied across acute trusts, from\u00a0<\/span>0.0%<\/span><\/b>\u00a0at the lowest end to\u00a0<\/span>7.7%<\/span><\/b>\u00a0at the highest end.\u00a0<\/span>\u00a0<\/span><\/p>\n

This variation is one of the most important signals in the elective recovery data. National averages can show improvement while individual providers and systems\u00a0remain\u00a0far from the level of access patients should expect. For patients, this means the experience of elective recovery\u00a0remains\u00a0highly dependent on geography and local pathway performance.<\/span>\u00a0<\/span><\/p>\n

For NHS leaders, variation changes the recovery question. The issue is not only whether national performance improves. It is whether improvement can be made consistent across systems,\u00a0specialties\u00a0and providers.<\/span>\u00a0<\/span><\/p>\n

This is where targeted recovery support becomes important. The system does not need unfocused activity that sits outside local governance. It needs capacity that is clinically prioritised, operationally integrated, properly assured and aligned to provider-level recovery plans.<\/span><\/p>\n

Diagnosticsremaina constraint on elective recovery\u00a0<\/span><\/h3>\n

Elective recovery cannot be separated from diagnostic capacity.<\/span>\u00a0<\/span><\/p>\n

The March Integrated Performance Report shows that\u00a0<\/span>24.7%<\/span><\/b>\u00a0of patients were waiting over six weeks for a diagnostic procedure or test in January 2026. This was slightly better than December 2025, but worse than January 2025, when the figure was\u00a0<\/span>22.4%<\/span><\/b>. NHS England attributes this to activity growth\u00a0failing to keep\u00a0pace with demand growth, with diagnostic activity growth at\u00a0<\/span>3.3% year to date to December 2025<\/span><\/b>\u00a0compared with demand growth of\u00a0<\/span>3.6%<\/span><\/b>.\u00a0<\/span>\u00a0<\/span><\/p>\n

This matters because diagnostics sit upstream of treatment. Where diagnostic waits lengthen, elective treatment decisions are delayed. Cancer pathways are also affected. In January 2026, the Faster Diagnosis Standard was\u00a0<\/span>72.8%<\/span><\/b>, while the 62-day combined cancer standard was\u00a0<\/span>68.4%<\/span><\/b>\u00a0against the 80% planning guidance ambition.\u00a0<\/span>\u00a0<\/span><\/p>\n

The diagnostic signal should not be overstretched. This blog is focused on elective recovery, not a full diagnostic deep dive. But it is impossible to assess elective recovery honestly without recognising that diagnostic performance is one of the key constraints on the pathway.<\/span>\u00a0<\/span><\/p>\n

For leaders, the message is clear: elective recovery cannot be treated as a theatre-only or outpatient-only challenge. It depends on the whole pathway. If diagnostic bottlenecks persist, headline waiting-list reductions may become harder to sustain.<\/span><\/p>\n

Productivity and financial grip will shape the next phase<\/h3>\n

The March Board pack also places elective recovery inside a tighter financial and productivity environment.<\/span>\u00a0<\/span><\/p>\n

The Month 10 finance paper reports that the NHS was broadly in balance nationally, with a\u00a0<\/span>\u00a371 million revenue overspend<\/span><\/b>\u00a0equal to\u00a0<\/span>0.04%<\/span><\/b>\u00a0of year-to-date allocation. But beneath that national position, systems were overspending by\u00a0<\/span>\u00a3428 million<\/span><\/b>\u00a0year to date, with 14 systems\u00a0formally forecasting year-end overspends. The paper\u00a0identifies\u00a0efficiency slippage, workforce costs above planned levels and industrial action cover among the drivers of variance.\u00a0<\/span>\u00a0<\/span><\/p>\n

This is highly relevant to elective recovery. In earlier phases of recovery,\u00a0additional\u00a0activity could often be framed primarily as a capacity response. In 2026\/27, that will not be enough. Capacity will need to\u00a0demonstrate\u00a0value, productivity, clinical\u00a0safety\u00a0and alignment with system financial plans.<\/span>\u00a0<\/span><\/p>\n

The Strategy Committee reinforces this direction. It reviewed a Productivity Plan aimed at achieving\u00a0<\/span>2% annual productivity growth<\/span><\/b>, with reducing unwarranted variation identified as the core strategy for baseline productivity gains. The Committee also highlighted expanded day-case surgery, scaled diagnostic models and artificial intelligence as examples of more disruptive innovation to shift the productivity frontier.\u00a0<\/span>\u00a0<\/span><\/p>\n

The Committee\u2019s forward project pipeline also includes an Elective Care Strategy, which means elective recovery is moving from an operational recovery issue into a more structured strategic programme.\u00a0<\/span>\u00a0<\/span><\/p>\n

The practical implication is that elective support will increasingly be judged against four tests: does it improve access, protect safety, support\u00a0productivity\u00a0and fit within financial discipline?<\/span>\u00a0<\/span><\/p>\n

What this means now<\/h3>\n

The March Board papers show that elective recovery is improving, but still fragile.<\/span>\u00a0<\/span><\/p>\n

The waiting list is falling. Long waits are reducing. Children and young people\u2019s waits are lower than a year earlier. RTT performance has improved. These are positive system signals. But they sit alongside\u00a0a very large\u00a0residual waiting list, an 18-week performance gap, significant provider variation, diagnostic constraint, cancer pathway\u00a0pressure\u00a0and a tighter financial environment.\u00a0<\/span>\u00a0<\/span><\/p>\n

For NHS provider and system leaders, the next phase of elective recovery will require more than activity volume. It will require disciplined pathway management, targeted capacity, reliable clinical governance, diagnostic alignment, workforce\u00a0resilience\u00a0and productivity improvement.<\/span>\u00a0<\/span><\/p>\n

For patients, the issue is straightforward: improvement must translate into shorter,\u00a0safer\u00a0and more consistent waits. For healthcare workers, the risk is that recovery pressure becomes another layer of operational intensity unless capacity is planned carefully and delivered in a way that supports, rather than destabilises, existing teams.<\/span>\u00a0<\/span><\/p>\n

The central system implication is this:\u00a0<\/span>elective recovery will become secure only when the NHS can reduce waits while also reducing variation, protecting safety and improving productivity.<\/span><\/b>\u00a0<\/span><\/p>\n

That is the standard against which the next phase of recovery should be judged.<\/span>\u00a0<\/span><\/p>\n

References<\/h3>\n

NHS England,\u00a0<\/span>Integrated Performance Report<\/span><\/i>, March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Month 10 financial position 2025\/26<\/span><\/i>, March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Board Committee updates \u2013 NHS England Strategy Committee<\/span><\/i>, March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Meeting of the Board of NHS England \u2013 agenda<\/span><\/i>, 26 March 2026.\u00a0<\/span>
\nNHS England,\u00a0<\/span>Minutes of a public meeting of the NHS England Board held on Thursday 5 February 2026<\/span><\/i>, published March 2026.\u00a0<\/span>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

The March 2026 NHS England Board papers show that elective recovery is moving in the right direction, but not yet on secure footing.\u00a0 The total elective waiting list has reduced. Long waits are falling. The under-18 waiting list is lower than a year earlier. Referral to Treatment performance has improved compared with January 2025. These…<\/p>\n","protected":false},"author":26,"featured_media":63128,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","footnotes":""},"categories":[25],"tags":[],"class_list":["post-63123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-leadership"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/comments?post=63123"}],"version-history":[{"count":1,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63123\/revisions"}],"predecessor-version":[{"id":63129,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/posts\/63123\/revisions\/63129"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/media\/63128"}],"wp:attachment":[{"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/media?parent=63123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/categories?post=63123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.promedical.co.uk\/af-api\/wp\/v2\/tags?post=63123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}